Open Access

The threat of antimicrobial resistance in developing countries: causes and control strategies

Antimicrobial Resistance & Infection Control20176:47

DOI: 10.1186/s13756-017-0208-x

Received: 5 February 2017

Accepted: 10 May 2017

Published: 15 May 2017

Abstract

The causes of antimicrobial resistance (AMR) in developing countries are complex and may be rooted in practices of health care professionals and patients’ behavior towards the use of antimicrobials as well as supply chains of antimicrobials in the population. Some of these factors may include inappropriate prescription practices, inadequate patient education, limited diagnostic facilities, unauthorized sale of antimicrobials, lack of appropriate functioning drug regulatory mechanisms, and non-human use of antimicrobials such as in animal production. Considering that these factors in developing countries may vary from those in developed countries, intervention efforts in developing countries need to address the context and focus on the root causes specific to this part of the world. Here, we describe these health-seeking behaviors that lead to the threat of AMR and healthcare practices that drive the development of AMR in developing countries and we discuss alternatives for disease prevention as well as other treatment options worth exploring.

Keywords

Antimicrobial therapy Developing countries Microorganisms Resistance

Background

The threat of antimicrobial resistance (AMR) is growing at an alarming rate and the situation is perhaps aggravated in developing countries due to gross abuse in the use of antimicrobials [1]. It is well known that any use of antimicrobials however appropriate and justified, contributes to the development of resistance, but widespread unnecessary and excessive use makes the situation worse [2]. Misuse of antimicrobials is facilitated in developing countries by their availability over the counter, without prescription and through unregulated supply chains [1, 3]. Non-compliance in the use of antimicrobials has many repercussions upon resistance and poverty is a major root factor of antimicrobial misuse in developing countries [4]. On the other hand, even among the rich, some patients miss doses either by mistake or deliberate, especially in cases where signs and symptoms begin to subside after an initial favorable therapeutic response [5]. In other situations, such as in the event of an acute side effect, patients abandon their treatment, only to return to the hospital with a recurring infection by a more virulent and resistant strain of the microbe [6]. These actions result in the exposure of surviving pathogens to sub-therapeutic concentrations of antimicrobials thus increasing the chances of acquiring resistance. Self-medication is a common practice in developing countries where patients often get antimicrobials without prescription and through unregulated supply chains [7]. To make the situation even worst, some patients seek their first-line of treatment from traditional healers who provide them with herbal combinations for the treatment of infections. These substances of unknown composition and potency may enhance pathogen fitness and contribute to the development of resistance. Antimicrobial resistance often occur through the inhibition of specific antimicrobial pathways such as cell wall synthesis, nucleic acid synthesis, ribosome function, protein synthesis, folate metabolism, and cell membrane function [810].

Causes of antimicrobial resistance

To better appreciate the causes of AMR, we need to understand the various sequential steps involved for a drug to get to a patient and the eventual use, which include; production, distribution, prescription, dispensing, and finally consumption of the drug by the patient or use in animal production [11]. Consequently, any imprudent practice along this flow may result in the emergence of resistance.

Drug dispensers and drug quality

The lack of appropriate regulations in the sales of antimicrobials is also a driving factor in the access and misuse of antimicrobials. In most developing countries, antimicrobials can be purchased without medical prescription [12] and are usually dispensed on the streets by untrained persons. These drug vendors will sell medications just to make a sale and accommodate patients’ ability to pay [13]. Even pharmacies operating without a license, appear to be more accessible to the public as they have shorter waiting time, do not charge consultation fees and above all are willing to negotiate treatment options to adjust to the financial ability of the patients [14]. Retail pharmacies in developing countries especially in Africa have emerged as the primary level of outpatient care rendering unauthorized services from consultation, diagnosis, prescription and dispensing of medication [14, 15].

It has also been shown that many antimicrobials dispensed in Africa are of questionable pharmacological quality [16, 17]. Adverse climatic conditions such as high ambient temperatures and humidity may affect the overall quality of the antimicrobials during storage [18, 19]. Poor storage also increases the risk of degradation of the drug. Degraded medicines contain less than stated dose, implying that patients consume less than optimal dose of the drug. There is also a problem of outright counterfeit, in which the drug may contain little or no active substance of the antimicrobial or the wrong substance [20]. The influx of counterfeit and sub-standard antimicrobials into the pharmaceutical markets in some regions is a major problem as these preparations of reduced potency also result in pathogens being exposed to sub-therapeutic concentrations of the drug [21]. A study from Cameroon revealed that, out of 284 antimalarial obtained from 132 vendors, 32% of chloroquine, 10% quinine, and 13% sulfadoxine/pyrimethamine were likely to be fake [16]. In addition, some of the quinine contained chloroquine while some chloroquine contained no active ingredient or an amount lower than the expected concentration.

Health professionals

Health care providers play an essential role in the treatment and prevention of diseases, but may jeopardize this if their practices are not evidence-based (Table 1). For example, the prescription practices of antimicrobials vary among physicians in most countries. In some cases, the antimicrobial prescriptions are inappropriate (i.e., wrong drug, wrong doses, or antimicrobial not necessary at all) [22]. Due to the high patient-doctor ratio in most developing countries, doctors are overwhelmed and there is often inadequate time for meaningful education and communication with the patient on drug adherence guidelines and consequences of poor or non-adherence to these guidelines. Treatment sometimes consists of administering broad-spectrum antibiotics without a definitive diagnosis and indication for antimicrobial treatment. In a Lebanese study, it was shown that in 52% of cases, the prescription dose was inappropriate while 63.7% of physicians prescribed antibiotics with wrong duration of treatment [23].
Table 1

Factors and stakeholders contributing to the problem of antimicrobial resistance

Factors

Contribution

Example

Poor drug quality

Sales of counterfeit, adulterated and poor quality antibiotics

These poor quality antibiotics can produce sub-inhibitory concentration in vivo, which increases the selection of resistant strains

Regulators

While most developed countries have developed AMR action plans, this is still lacking in many developing countries especially in Africa

Most countries lack the resources to enforce policies regarding the manufacture and distribution of sub-standard drugs

Prescribers

Excessive clinical use and misuse is partially responsible for increase rate of resistance

Variation in prescription practice among health care provider. Sometimes there is prescription of a wrong drug, wrong doses, or antimicrobial not necessary at all

Dispensers

Drug vendors usually have little or no knowledge of the required dosage regimen, indication, or contraindications

Medications are usually purchased in small aliquots from roadside stall and storage and distribution is usually done under inadequate conditions

Users (patients)

High rate of self- medication and lack of treatment compliance

Patients fail to adhere to dosage regimens and discontinue treatment when symptoms subside before pathogen is eliminated

Animal industry

The use of antimicrobial drugs in agriculture or industrial settings, exerts a selection pressure which can favor the survival of resistant strains (or genes) over susceptible ones, leading to a relative increase in resistant bacteria within microbial communities

Resistant bacteria in animals can be transferred to humans through the consumption of food or through direct contact with food-producing animals or through environmental spread

Due to lack of effective and reliable surveillance systems and poor dissemination of research information, health professionals in developing countries sometimes lack up to date information on the AMR pattern within their populations. In tertiary hospitals with advanced capacities, physicians rely mostly on the resistance or susceptibility pattern of the pathogen isolated from a patient. Health personnel in rural settings without the capacity to do AMR testing have difficulty to decide on the choice of antimicrobial in the absence of an antimicrobial sensitivity test. As a result, health professionals use more and more broad-spectrum antibiotics to treat infections caused by several bacteria species or those for which establishing the etiology is difficult or takes a long time. This practice contributes to the development of resistance [24] as the drug applies selective pressure, not only upon the etiological agent of the disease episode but also upon a large fraction of the patient’s microbiota [25]. Some health professionals issue prescriptions that are not evidence-based and rely on a syndromic approach to both infections in the community as well as hospitalized patients. That is treatment is based on easily recognized signs and symptoms (syndromes) as well as to microorganism most commonly responsible for each of these syndromes. This practice is on the rise due to the lack of legal consequences of wrongful prescription of antibiotics. Our preliminary findings in Cameroon revealed that a significant number of physicians are likely to prescribe antibiotics to treat diarrhea caused by rotavirus, due to the lack of capacity to establish the diagnosis (Unpublished). Due to fear of bad treatment outcomes of critical diseases, some physicians may resort to blind prescription of multiple and broad-spectrum antimicrobials. Meanwhile, because of financial incentives from drug suppliers, some physicians are prone to prescribing multiple antibiotics for the same condition [26].

Patients

As mentioned earlier, compliance is a major contributor to the development of AMR [27]. Patients miss doses, either by mistake or deliberate. Because patients are aware of the adverse impact of drinking alcohol while on antibiotics, some patients may skip doses when invited for a party in favor for the consumption of alcohol (unpublished data). These practices result in exposure of surviving microbes to sub-therapeutic concentrations of the drug and, consequently increases the chances of developing resistance [25]. Because of poverty, many sick individuals in developing countries of Africa often seek their first-line of treatment from traditional healers who provide them with herbal mixtures of unknown efficacy for the treatment of infections. Some combine antibiotics with their herbal mixtures simultaneously while others take antimicrobials and supplement them with herbal mixtures purportedly to improve efficacy [12]. These compounds of unknown potency may enhance pathogen fitness.

Non-human use of antimicrobials

Antimicrobials are used to prevent (prophylaxis in high risk animals) and treat diseases in animals, as well as used as growth promoters in animal breeding [28, 29]. Additionally, they are used as additives in plant agriculture (fruits, vegetables, and orchid, etc.), especially in the spraying of fruit trees for disease prophylaxis and the application of antibiotic-containing manure on farmland and in industrial processes [30]. The use of antimicrobial agents in animals and more importantly food-producing animals has important consequences for both human and animal health as it can lead to the development of resistant bacteria (Table 1). These resistant bacteria (with resistance genes) in animals can be transferred to humans through the consumption of food or through direct contact with food-producing animals or through environmental spread (e.g. human sewage and runoff water from agricultural sites). The use of antimicrobial drugs in health care, agriculture or industrial settings, exerts a selection pressure which can favor the survival of resistant strains (or genes) over susceptible ones, leading to a relative increase in resistant bacteria within microbial communities [31]. It is now known that increased AMR in bacteria affecting humans and animals is primarily influenced by an increase in the use of antimicrobials for a variety of purposes, including therapeutic and non-therapeutic purposes in animal production [32]. A strong association between agricultural use of antimicrobials and the development of resistance has been suggested [33], and it has been shown that the bulk of antimicrobials used worldwide are not consumed by humans but rather are given to animals for the purposes of food production [34].

Multidrug resistant bacteria have been detected in both meat and fresh produce [35] and in humans in contact with livestock in many African countries [3638]. A study in Kenya revealed a high level of antimicrobial drug residues in meat meant for consumption [34]. These findings further demonstrate that food animals are a major reservoir of drug resistant bacteria and present a major risk for dissemination and transmission of antimicrobial resistant bacteria in Africa as well as many developing countries. A large proportion of the population in developing countries live in close proximity with animals, thus increasing the chances of transmission of resistant microorganisms from animals to humans through animal handling [39, 40]. In a recent study in rural Bangladesh animal healthcare providers responded they more often sought animal health care from pharmacies and village doctors, citing the latter two as less costly and more successful based on past performance [41]. In the absence of an effective animal healthcare system, villagers depend on informal healthcare providers for treatment of their animals. This may lead to suboptimal use of antimicrobials in such settings with unhygienic animal husbandry practices. In terms of aquaculture, heavy use of prophylactic antibiotics in aquaculture has been reported in developing countries and is a growing problem for human and animal health and for the environment [42].

Overall, limiting the routine use of in-feed antibiotics will improve human and animal health, by reducing the development and spread of antibiotic-resistant bacteria. Therefore, judicious use of antibiotics in healthcare and agricultural settings is essential to slow the emergence of resistance and extend the useful lifetime of effective antibiotics that are in existence today.

In other to minimize the risk of AMR due to non-human use of antimicrobials especially in animal production, information resources in developing countries need to be strengthened to support health professionals, patients, animal keepers and the public, so that the society can have a better understanding of the value and importance of antimicrobials, especially antibiotics. Taken together, the excessive use of antimicrobials in animals and agriculture and the associated public health consequences justifies the importance of limiting the inappropriate use of antimicrobials in both agriculture and the veterinary sector.

Inadequate surveillance and limited laboratory antimicrobial susceptibility testing

The availability of routine antimicrobial susceptibility testing to provide information on resistance trends, including emerging resistance is very essential for routine clinical practice and for the development of effective policies against AMR. Antimicrobial susceptibility testing is not often performed in most rural laboratories due to lack of capacity. In the absence of patient-specific antimicrobial susceptibility testing, community-based antimicrobial surveillance data may be very useful to health care professionals in particular communities or regions to treat infections with specific susceptible antimicrobials. Such surveillance needs to be conducted regularly and continuously because resistance rates can vary in one region of a country over time.

Antimicrobial resistance control strategies

The problem of AMR is aggravated by the fact that most world pharmaceutical companies consider research for new antimicrobials as being of “low profit” and some speculate that resistance will eventually develop for new antimicrobials anyway. Consequently, they prefer to invest in the development of drugs for chronic diseases (diabetes, hypertension) as well as those used to improve lifestyle (e.g., Cialis, Viagra, etc.) [43]. Therefore, the long-term solution should be focused on methods to prevent the emergence of resistance or the spread of resistant organisms from one person to another.

Hygiene and sanitation

Apart from the irrational use of antimicrobials, unique environmental conditions such as crowding and poor sanitation also contribute in the circulation and spread of resistant microorganisms. Transmission of resistant pathogens is facilitated by person-person contact, through contaminated water, food or by vectors. Improving basic hygiene and sanitation will reduce the spread of resistant organisms (Table 2) [44]. Improving infection prevention and control in hospitals will reduce the nosocomial spread of bacteria with acquired resistance such as Staphylococcus aureus amongst others.
Table 2

Strategies to contain and minimize the development of antimicrobial resistance

Control strategies

Contribution

Hygiene and sanitation

Improving basic hygiene and sanitation will reduce the spread of resistant organisms

Vaccination

Vaccination may reduce severity of disease, provide protection against shedding of pathogens and even raise the threshold load of pathogens required for infection

Alternative therapies

The reluctance of pharmaceutical companies to invest in research and development of novel antimicrobial agents necessitate the exploration of alternative therapies such as bacteriophage, probiotics and Quorum Sensing inhibitors

Education

Health care providers, dispensers and patients need to be educated on how the use and misuse of antimicrobial may contribute to the development of resistance

Infection prevention & control

Proper hospital infection control may prevent the spread of nosocomial pathogens and resistant microbes that may have easily been disseminated to the community if these measure were not in place

Vaccination

While antimicrobials are used for treatment, vaccines are a primary mode of prevention of infectious diseases. Prior vaccination may reduce severity of disease, provide protection against shedding of pathogens and even raise the threshold load of pathogens required for infection [4547]. Also, indirect population protection of some vaccines as a result of herd immunity in unvaccinated individuals represents additional advantage of vaccination. In most regions of the world, a number of diseases such as smallpox, measles, mumps rubella, diphtheria, hepatitis A, pertussis, and polio have been prevented by vaccination [48].

However, even with the most effective vaccine, the need of antimicrobials or alternative treatment options will still in some cases be solicited. For example, in the case of genetic drift, escape mutants and serotype or strain replacement diseases, vaccination may fail to confer full protection from disease. For bacterial infections, the introduction of conjugate vaccines for example Streptococcus pneumoniae, has reduced the outbreak of respiratory infections in children in developing countries [49].

Alternative therapies

The increase in microbial resistance to traditional antimicrobials and the reluctance of pharmaceutical companies to invest in research and development of novel antimicrobial agents necessitate the exploration of alternative therapies. Future focus of medical therapeutics and research is to look beyond antibiotics [43], and search for alternatives which can regulate the microbial virulence as well as growth inhibition. There are currently a couple of other alternatives approaches at different levels of research and development.
  1. 1.

    The use of bacteriophage is emerging as an alternative treatment option for bacteria infections [50]. Many authors have suggested that bacteriophage therapy is a necessary alternative to conventional antibiotics [51, 52]. Bacteriophages are bacterial viruses with the capacity to invade bacterial cells and induce lysis of the bacteria (lytic cycle). In the present era of multidrug resistant bacteria and reluctance in the development of new antibiotics by pharmaceutical companies, the need to aggressively explore the possibility of phage therapy is unprecedented.

     
  2. 2.

    Quorum Sensing inhibitors represents an important antimicrobial target that may prevent, suppress, and/or treat infectious diseases. The mechanistic details (including auto-inducers) of Quorum Sensing are different between Gram-negative and Gram-positive bacteria. Gram-negative bacteria utilize N-acyl l-homoserine lactones (AHLs), which are homoserine lactone (HSL) rings with an additional fatty acid side chain while Gram positive bacteria uses oligopeptides [5355]. While antibiotics kill or slow down the growth of bacteria, quorum sensing inhibitors or quorum quenchers simply attenuate bacterial virulence. A large body of work on Quorum Sensing has been carried out in deadly pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, Vibrio fischeri, Vibrio. harveyi, Escherichia coli and Vibrio. cholerae etc. A number of these studies have succeeded in exploiting the bacterial Quorum Sensing system as potential target for treatment of bacterial infections. The inhibition of Quorum Sensing system is believed to be advantageous over conventional antibiotics, because only the communication mechanism between the bacteria is disrupted without killing the individual cells. Hence, this strategy should generate a lower selective pressure and reduce the rate at which AMR develops during the treatment [55].

     
  3. 3.

    Probiotics, otherwise referred to as fecal transplant therapy (FTT) is a treatment option that has been employed for decades, albeit with mixed results [5658]. FTT is the act of using fecal material from pathogen-free healthy donors to repopulate the microbiota of a recipient. Probiotics are considered to be able to destroy pathogenic microorganisms by producing antimicrobial compounds such as bacteriocins and organic acids, improve gastrointestinal microbial environment by adherence to intestinal mucosa thereby preventing attachment of pathogens and competing with pathogens for nutrients, stimulate the intestinal immune responses and improve the digestion and absorption of nutrients. The commonly used probiotics include Bacillus, Lactobacillus, Lactococcus, Streptococcus, Enterococcus, Pediococcus, Bifidobacterium, Bacteroides, Pseudomonas, yeast, Aspergillus, and Trichoderma, etc.

     

This treatment option is an old practice, used many years ago, especially in China and had been successfully used to treat Clostridium difficile infections as well as other enteric diseases [56, 59, 60].

Taken together, the application of these alternate therapies is not limited to developing countries and most are still under development or at different stages of clinical trial and their routine availability will require governmental approval and subvention in developing countries.

The role of stakeholders in the control of antimicrobial resistance

The control of AMR cannot be the sole responsibility of medical professionals and scientists. Although continuing education is essential to enable health care providers learn the need in rational prescription practices and the importance of evidence-based prescription [61], the general population and other stakeholders have a central role to play [62]. The government of every country should consider AMR as a public health priority issue. Policies and regulations should be put in place to enforce the prudent access and use of antimicrobials. The population needs to be educated on the threat of AMR and therefore media professionals need to get adequate training on how to convey medical and scientific information in lay language through multiple channels to inform the populations on practices that promote the emergence of AMR organisms [62]. The benefits of an education program for journalists has been successful for the fight against HIV/AIDS in many developing countries and a similar approach for AMR will likely result to an added benefit [63, 64]. A number of initiatives have been taken so far by regulatory agencies and governments in the combat of antimicrobial resistance but most of these initiatives have been done only in developed countries [6568] and are lacking in resource limited nations [69, 70].

A few African countries have been identified as being involved in the Global Antibiotic Resistance Partnership (GARP), established in 2009 to create a platform for developing actionable policy proposals on antibiotic resistance in low-income and middle-income countries. Unfortunately, to date national GARP working groups are established only in a few African countries [70]. There is therefore need to generate solutions such as to build a strong African laboratory infrastructure to help combat AMR which is a global health threat [71]. A multi-disciplinary approach involving a wide range of partners is therefore needed to limit the risk of AMR and minimize its impact on human and animal health especially in developing countries.

The role of government regulatory agencies

With the new and emergent issue regarding the development of AMR, government agencies globally have engaged in new action plans in order to combat the AMR issue [72]. However, actions toward this has been severely lacking in developing countries especially those in Africa where high quality regulatory agencies are lacking. In May 2015, the WHO endorsed a global action plan to tackle AMR [73]. In September 2014, the US government released a ‘National Strategy for Combating Antibiotic-Resistant Bacteria’ that included an executive order signed by the US president [68]. The action plan provided several goals and a roadmap to guide the Nation in rising to this challenge. In 2013, the United Kingdom released the ‘UK Five Year Antimicrobial Resistance Strategy (2013 to 2018)’ that sets out actions to address the key challenges to AMR [67]. Similarly, in 2015, the government of Canada also released the Federal Action Plan on antimicrobial resistance and use in Canada (Building on the federal framework for action) [66]. While many developed countries have developed such AMR action plans either nationally or at the regional level such as the European Union and Asia-Pacific region, this is still lacking in many developing countries especially in Africa [69]. A few African countries have been identified as being involved in the Global Antibiotic Resistance Partnership (GARP), established in 2009 to create a platform for developing actionable policy proposals on antibiotic resistance in low-income and middle-income countries. However, national GARP working groups are established only in India, Kenya, South Africa, Vietnam, Mozambique, Nepal, Tanzania and Uganda. Moreover, a close look at the national action plans showed that only one African country (Ethiopia), was identified by the WHO as having a national AMR action plan [74] .

What most developing countries especially those in Africa lack is not the legislation prohibiting the manufacture and distribution of sub-standard drugs but resources to enforce these policies and to impose penalties to defaulters. There is also lack of resources to identify counterfeit drugs or verify the quality of locally manufactured or imported drugs [75]. In addition, governments need to address the sale of antimicrobials without prescription and illegalize the dispensing of drugs by unauthorized and unqualified persons. There is also need for the population to be sensitized on the public health risks of AMR. A recent WHO survey revealed that while much activity is underway and many governments are committed to addressing the AMR problem, there are major gaps in actions needed across all 6 WHO regions to prevent the misuse of antibiotics and reduce spread of AMR [69]. Despite these challenges some progress is currently being made in setting up drug regulatory agencies in Africa. The effort is supported by the New Partnership for Africa’s Development (NEPAD) of the African Union and the WHO. Through the creation of the African Medicines Regulatory Harmonization (AMRH), it is envisioned that safe, good quality, efficacious and reasonably priced medicines will be available in Africa [76]. Recently, the African Society for Laboratory Medicine (ASLM) has engaged in activities to share research, debate, and generate solutions to build a strong African laboratory infrastructure to help combat common global health threats, like AMR as well as HIV/AIDS, and other medical conditions [71]. Therefore, a multi-disciplinary approach involving a wide range of partners is therefore needed to limit the risk of AMR and minimize its impact on human and animal health especially in developing countries.

Conclusions

The irrational use of antimicrobials is certainly a complex and multifactorial problem in developing countries, and a proper understanding of the problem is necessary for effective control policies. Without effective antimicrobials, diverse medical procedures such as surgery, the care of premature infants, cancer chemotherapy, care of the critically ill, invasive diagnostic and treatment procedures, and transplantation medicine will be severely hampered with a corresponding increase in morbidity and mortality from secondary microbial infections. The challenge of global antimicrobial resistance is comparable to climate change and global warming. Therefore, as we seek to protect the climate for the future generation, it is our responsibility not to pass over to the next generation, microbial population that is resistant to antimicrobial agents that they are supposed to treat as the consequence is likely to be very dangerous.

Abbreviations

AIDS: 

Acquired immunodeficiency syndrome

AMR: 

Antimicrobial resistance

FTT: 

Fecal transplant therapy

HIV: 

Human immunodeficiency virus

GARP: 

Global antibiotic resistance partnership

Declarations

Acknowledgement

Not applicable.

Funding

Not applicable.

Availability of data and materials

“Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions

JAA did the initial literature search, wrote the first draft as well as coordinated the writing of the entire manuscript; MN designed the outline, performed literature search and contributed in writing; and ANA reviewed the first draft, provided relevant editing as well as writing and performed reference formatting. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent participation

Not applicable.

Disclaimer

The views in this review do not necessarily reflect those of Health Canada, the University of Ottawa and Metabiota Inc.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Section for Clinical Microbiology, Redeem Biomedical
(2)
Human Safety Division, Veterinary Drugs Directorate, Health Products and Food Branch, Health Canada
(3)
School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa
(4)
Metabiota Inc.

References

  1. Byarugaba DK. A view on antimicrobial resistance in developing countries and responsible risk factors. Int J Antimicrob Agents. 2004;24:105–10.View ArticlePubMedGoogle Scholar
  2. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057–98.View ArticlePubMedGoogle Scholar
  3. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, et al. Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect. Dis. 2005;5:568–80.Google Scholar
  4. Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect. Dis. 2005;5:481–93.Google Scholar
  5. Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ. 1998;317:647–50.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999;5:18–27.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Kunin CM. Resistance to antimicrobial drugs--a worldwide calamity. Ann Intern Med. 1993;118:557–61.View ArticlePubMedGoogle Scholar
  8. Fluit AC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin Microbiol Rev. 2001;14:836–871, table of contents.
  9. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8:423–35.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev. 1996;19:1–24.View ArticlePubMedGoogle Scholar
  11. Quick J, Bremer K. Quality control of essential drugs. Lancet Lond Engl. 1997;350:1106.View ArticleGoogle Scholar
  12. Lansang MA, Lucas-Aquino R, Tupasi TE, Mina VS, Salazar LS, Juban N, Limjoco TT, Nisperos LE, Kunin CM. Purchase of antibiotics without prescription in Manalia, the Philippines. Inappropriate choices and doses. J Clin Epidemiol. 1990;43:61–7.
  13. Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis. 2007;13:1640–6.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Goel P, Ross-Degnan D, Berman P, Soumerai S. Retail pharmacies in developing countries: a behavior and intervention framework. Soc Sci Med. 1996;42:1155–61.View ArticlePubMedGoogle Scholar
  15. Kwena Z, Sharma A, Wamae N, Muga C, Bukusi E. Provider characteristics among staff providing care to sexually transmitted infection self-medicating patients in retail pharmacies in Kibera slum, Nairobi. Kenya Sex Transm Dis. 2008;35:480–3.View ArticlePubMedGoogle Scholar
  16. Basco LK. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. AmJTrop Med Hyg. 2004;70:245–50.Google Scholar
  17. Winstanley P, Ward S, Snow R, Breckenridge A. Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy. Clin Microbiol Rev. 2004;17:612–37.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Okeke IN, Lamikanra A. Quality and bioavailability of ampicillin capsules dispensed in a Nigerian semi-urban community. Afr J Med Med Sci. 2001;30:47–51.PubMedGoogle Scholar
  19. Risha PG, Shewiyo D, Msami A, Masuki G, Vergote G, Vervaet C, et al. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop Med Int Health TM IH. 2002;7:701–7.View ArticlePubMedGoogle Scholar
  20. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2:e100.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother. 2007;60:214–36.View ArticlePubMedGoogle Scholar
  22. Usluer G, Ozgunes I, Leblebicioglu H, Turkish antibiotic utilization study group. A multicenter point-prevalence study: antimicrobial prescription frequencies in hospitalized patients in Turkey. Ann Clin Microbiol Antimicrob. 2005;4:16.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Saleh N, Awada S, Awwad R, Jibai S, Arfoul C, Zaiter L, et al. Evaluation of antibiotic prescription in the Lebanese community: a pilot study. Infect Ecol Epidemiol. 2015;5:27094.View ArticlePubMedGoogle Scholar
  24. Neu HC. The crisis in antibiotic resistance. Science. 1992;257:1064–73.View ArticlePubMedGoogle Scholar
  25. Calva J, Bojalil R. Antibiotic use in a periurban community in Mexico: a household and drugstore survey. Soc Sci Med. 1996;42:1121–8.View ArticlePubMedGoogle Scholar
  26. Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy. 2009;90:32–6.View ArticlePubMedGoogle Scholar
  27. Malfertheiner P. Compliance, adverse events and antibiotic resistance in helicobacter pylori treatment. Scand J Gastroenterol. 1993;28:34–7.View ArticleGoogle Scholar
  28. Collignon P, Wegener HC, Braam P, Butler CD. The routine use of antibiotics to promote animal growth does little to benefit protein undernutrition in the developing world. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc Am. 2005;41:1007–13.View ArticleGoogle Scholar
  29. Petersen A, Andersen JS, Kaewmak T, Somsiri T, Dalsgaard A. Impact of integrated fish farming on antimicrobial resistance in a pond environment. Appl Environ Microbiol. 2002;68:6036–42.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Vidaver AK. Uses of antimicrobials in plant agriculture. Clin Infect Dis Off Publ Infect Dis Soc Am. 2002;34(Suppl 3):S107–10.View ArticleGoogle Scholar
  31. Witte W. Medical consequences of antibiotic use in agriculture. Science. 1998;279:996–7.View ArticlePubMedGoogle Scholar
  32. Food and Agriculture Organization. Drivers, dynamics and epidemiology of antimicrobial resistance in animal production. [Internet]. FAO; 2016 [cited 2017 Jan 4]. Available from: http://www.fao.org/3/a-i6209e.pdf
  33. Aarestrup F. Sustainable farming: get pigs off antibiotics. Nature. 2012;486:465–6.View ArticlePubMedGoogle Scholar
  34. Mitema ES, Kikuvi GM, Wegener HC, Stohr K. An assessment of antimicrobial consumption in food producing animals in Kenya. J Vet Pharmacol Ther. 2001;24:385–90.View ArticlePubMedGoogle Scholar
  35. Mezali L, Hamdi TM. Prevalence and antimicrobial resistance of Salmonella isolated from meat and meat products in Algiers (Algeria). Foodborne Pathog Dis. 2012;9:522–9.View ArticlePubMedGoogle Scholar
  36. Addis Z, Kebede N, Sisay Z, Alemayehu H, Wubetie A, Kassa T. Prevalence and antimicrobial resistance of Salmonella isolated from lactating cows and in contact humans in dairy farms of Addis Ababa: a cross sectional study. BMC Infect. Dis. [Internet]. 2011 [cited 2017 Jan 24];11. Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-11-222.
  37. Fortini D, Fashae K, García-Fernández A, Villa L, Carattoli A. Plasmid-mediated quinolone resistance and β-lactamases in Escherichia coli from healthy animals from Nigeria. J Antimicrob Chemother. 2011;66:1269–72.View ArticlePubMedGoogle Scholar
  38. Kikuvi GM, Ombui JN, Mitema ES. Serotypes and antimicrobial resistance profiles of Salmonella isolates from pigs at slaughter in Kenya. J Infect Dev Ctries. 2010;4:243–8.View ArticlePubMedGoogle Scholar
  39. Doyle ME. Multidrug-resistant pathogens in the food supply. Foodborne Pathog Dis. 2015;12:261–79.View ArticlePubMedGoogle Scholar
  40. Simango C, Rukure G. Potential sources of campylobacter species in the homes of farmworkers in Zimbabwe. J Trop Med Hyg. 1991;94:388–92.PubMedGoogle Scholar
  41. Roess AA, Winch PJ, Akhter A, Afroz D, Ali NA, Shah R, et al. Household animal and human medicine use and animal husbandry practices in rural Bangladesh: risk factors for emerging Zoonotic disease and antibiotic resistance. Zoonoses Public Health. 2015;62:569–78.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Cabello FC. Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment. Environ Microbiol. 2006;8:1137–44.View ArticlePubMedGoogle Scholar
  43. Brandenburg K, Schürholz T. Lack of new antiinfective agents: passing into the pre-antibiotic age? World J Biol Chem. 2015;6:71–7.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Smith MA, Garbharran H, Edwards MJ, O’Hara-Murdock P. Health promotion and disease prevention through sanitation education in south African Zulu and Xhosa women. J Transcult Nurs Off J Transcult Nurs Soc. 2004;15:62–8.View ArticleGoogle Scholar
  45. Hinman AR, Orenstein WA. Adult immunization: what can we learn from the childhood immunization program? Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;44:1532–5.View ArticleGoogle Scholar
  46. Iglehart JK. Health policy report. The centers for disease control. N Engl J Med. 1983;308:604–8.View ArticlePubMedGoogle Scholar
  47. Robinson CA, Bart KJ. Disease prevention through immunization: the beginning of health care reform. Public Health Rep. 1993;108:417–8.PubMedPubMed CentralGoogle Scholar
  48. van Panhuis WG, Grefenstette J, Jung SY, Chok NS, Cross A, Eng H, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med. 2013;369:2152–8.View ArticlePubMedPubMed CentralGoogle Scholar
  49. López EL, Glatstein E, Ezcurra GC, Iacono M, Teplitz E, Garnero AV, et al. Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina. J Pediatr Infect Dis Soc. 2017. doi:10.1093/jpids/piw089.
  50. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 1997;5:268–71.View ArticlePubMedGoogle Scholar
  51. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages show promise as antimicrobial agents. J Inf Secur. 1998;36:5–15.Google Scholar
  52. Mathur MD, Vidhani S, Mehndiratta PL. Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India. 2003;51:593–6.PubMedGoogle Scholar
  53. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as anti-pathogenic drugs. Int J Med Microbiol IJMM. 2006;296:149–61.View ArticlePubMedGoogle Scholar
  54. Williams P. Quorum sensing, communication and cross-kingdom signalling in the bacterial world. Microbiol Read Engl. 2007;153:3923–38.View ArticleGoogle Scholar
  55. Waters CM, Bassler BL. Quorum sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol. 2005;21:319–46.View ArticlePubMedGoogle Scholar
  56. Brandt LJ. Fecal transplantation for the treatment of Clostridium Difficile infection. Gastroenterol Hepatol. 2012;8:191–4.Google Scholar
  57. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009;136:2015–31.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Vrieze A, de Groot PF, Kootte RS, Knaapen M, van Nood E, Nieuwdorp M. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol. 2013;27:127–37.View ArticlePubMedGoogle Scholar
  59. Borody TJ, Brandt LJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: a new standard treatment option for Clostridium Difficile infection. Expert Rev Anti-Infect Ther. 2013;11:447–9.View ArticlePubMedGoogle Scholar
  60. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep. 2013;15:337.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Bhutta TI, Balchin C. Assessing the impact of a regulatory intervention in Pakistan. Soc Sci Med. 1996;42:1195–202.View ArticlePubMedGoogle Scholar
  62. Blakely JT-M, Sinkowitz-Cochran RL, Jarvis WR. Infectious diseases physicians’ preferences for continuing medical education on antimicrobial resistance and other general topics. Infect Control Hosp Epidemiol. 2006;27:873–5.View ArticlePubMedGoogle Scholar
  63. Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countries. J Int AIDS Soc. 2008;11:2.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Martinez-Cajas JL, Invernizzi CF, Ntemgwa M, Schader SM, Wainberg MA. The impact of the journalist-to-journalist program on worldwide HIV awareness. AIDS Lond Engl. 2008;22:1687–8.View ArticleGoogle Scholar
  65. World Health Organization. Global action plan on antimicrobial resistance [Internet]. 2015 [cited 2017 Jan 4]. Available from: http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1.
  66. Government of Canada. Federal action plan on antimicrobial resistance and use in Canada (building on the federal framework for action). Accessed [Internet]. 2015 [cited 2017 Jan 4]. Available from: http://healthycanadians.gc.ca/alt/pdf/publications/drugs-products-medicaments-produits/antibiotic-resistance-antibiotique/action-plan-daction-eng.pdf.
  67. Government of the United Kingdom. UK Five Year Antimicrobial Resistance Strategy 2013 to 2018 [Internet]. 2013 [cited 2017 Jan 4]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf.
  68. Government of the United States. National strategy for combating antibiotic-resistant bacteria. [Internet]. 2015 [cited 2017 Jan 4]. Available from: https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf.
  69. World Health Organization. WHO report finds systems to combat antibiotic resistance lacking [Internet]. 2015 [cited 2017 Jan 4]. Available from: http://www.who.int/mediacentre/news/releases/2015/antibiotic-resistance-lacking/en/.
  70. World Health Organization. Additional global, regional and national strategies and plans to address antimicrobial resistance [Internet]. 2014 [cited 2016 Dec 3]. Available from: http://www.cddep.org/garp/home.
  71. Africa Society for Laboratory Medicine. ASLM2016 helps to answer United Nations call to tackle threat of antimicrobial resistance. [Internet]. 2016 [cited 2017 Jan 4]. Available from: http://aslm2016.org/aslm2016-helps-to-answer-united-nations-call-to-tackle-threat-of-antimicrobial-resistance/.
  72. Tollefson L. Developing new regulatory approaches to antimicrobial safety. J Vet Med B Infect Dis Vet Public Health. 2004;51:415–8.View ArticlePubMedGoogle Scholar
  73. WHO. Global action plan on antimicrobial resistance. 2015 [cited 2017 Jan 5]; Available from: http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1.
  74. WHO. Additional global, regional and national strategies and plans to address antimicrobial resistance. 2014 [cited 2016 Dec 4]; Available from: http://www.who.int/drugresistance/global_action_plan/General_and_national_plans_amr_Dec_2014.pdf.
  75. Dua V, Kunin CM, White LV. The use of antimicrobial drugs in Nagpur, India. A window on medical care in a developing country. Soc Sci Med. 1994;38:717–24.View ArticlePubMedGoogle Scholar
  76. NEPAD. African Medicines Regulatory Harmonization (AMRH). 2016 [cited 2017 Jan 5]; Available from: http://www.nepad.org/content/african-medicines-regulatory-harmonisation-armh-programs?qt-programme_page=1.

Copyright

© The Author(s). 2017

Advertisement